Jin Medical International (ZJYL) Liabilities and Shareholders Equity (2022 - 2025)

Jin Medical International (ZJYL) has reported Liabilities and Shareholders Equity for 4 consecutive years, with $53.4 million the latest figure, recorded in Q3 2025.

• Quarterly Liabilities and Shareholders Equity rose 16.52% year-over-year to $53.4 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $188.9 million (up 25.16% YoY) and the FY2025 annual result came in at $53.4 million, up 16.52% from the prior year.
• Liabilities and Shareholders Equity rose to $53.4 million in Q3 2025 per ZJYL's latest filing, from $48.5 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for ZJYL reached as high as $53.4 million in Q3 2025 and fell as low as $20.9 million in Q3 2022.
• A 4-year average of $39.1 million and a median of $41.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity jumped 57.14% — and 2025, when it gained 16.52%.
• Year by year, Liabilities and Shareholders Equity stood at $20.9 million in 2022, then soared by 57.14% to $32.9 million in 2023, then soared by 39.2% to $45.8 million in 2024, then climbed by 16.52% to $53.4 million in 2025.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $53.4 million, $48.5 million, and $45.8 million for Q3 2025, Q1 2025, and Q3 2024 respectively.